Delivery and Biosafety of Oncolytic Virotherapy

Lizhi Li; Shixin Liu; Duoduo Han; Bin Tang; Jian Ma

doi:10.3389/fonc.2020.00475

Delivery and Biosafety of Oncolytic Virotherapy

Front Oncol. 2020 Apr 16:10:475. doi: 10.3389/fonc.2020.00475. eCollection 2020.

Authors

Lizhi Li^{1

2}, Shixin Liu^{1

2}, Duoduo Han^{1

2}, Bin Tang^{1

2}, Jian Ma^{1

2

3}

Affiliations

¹ Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
² Cancer Research Institute, School of Basic Medical Science, Xiangya School of Medicine, Central South University, Changsha, China.
³ Hunan Key Laboratory of Nonresolving Inflammation and Cancer, National Health Commission Key Laboratory of Carcinogenesis, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Changsha, China.

Abstract

In recent years, oncolytic virotherapy has emerged as a promising anticancer therapy. Oncolytic viruses destroy cancer cells, without damaging normal tissues, through virus self-replication and antitumor immunity responses, showing great potential for cancer treatment. However, the clinical guidelines for administering oncolytic virotherapy remain unclear. Delivery routes for oncolytic virotherapy to patients vary in existing studies, depending on the tumor sites and the objective of studies. Moreover, the biosafety of oncolytic virotherapy, including mainly uncontrolled adverse events and long-term complications, remains a serious concern that needs to be accurately measured. This review provides a comprehensive and detailed overview of the delivery and biosafety of oncolytic virotherapy.

Keywords: biosafety; delivery route; immunotherapy; oncolytic virotherapy; tumor.

Publication types

Review